Turning Point Therapeutics TPTX 深 沪
等待开盘 08-19 09:30:00 美东时间
76.01
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 76.01
- 总市值 38.06亿
- 52周最高 82.20
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 23.77
- 委 比 0.00%
- 总股本 5007.43万
- 历史最高 141.30
- 量 比 0
- 振 幅 0.00%
- 历史最低 23.77
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多TopBuild Completes Progressive Roofing Acquisition
TopBuild Corp. announced the completion of its $810 million all-cash acquisition of Progressive Roofing, a leader in U.S. commercial roofing services. Progressive Roofing generated $438 million in revenue and $89 million in EBITDA over the past year, with 70% of its revenue from non-discretionary re-roofing and maintenance. The acquisition expands TopBuild's building envelope solutions for general contractor customers and provides access to the $...
07-15 11:00
License-out火热的当下，他们将License-in这条路走通
备受冷落的License-in商业模式正迎来发展拐点。 近几年，在盈利的压力下，越来越多的Biotech选择了将自研管线License-out来获得首付款及里程...
2024-11-25 13:36
再鼎医药与Turning Point Therapeutics联手攻克耐药难题
再鼎医药宣布，奥凯乐（瑞普替尼）获中国NMPA批准治疗ROS1阳性非小细胞肺癌。FDA也已批准其用于相同适应证，并给予多项突破性治疗认定及快速通道资格。再鼎医药...
2024-05-13 15:27
再鼎医药(09688.HK)奥凯乐获国家药监局批准用于治疗ROS1阳性非小细胞肺癌患者
【财华社讯】再鼎医药(09688.HK)公布，奥凯乐®(瑞普替尼)已获中国国家药品监督管理局批准，用于治疗ROS1阳性的局部晚期或转移性非小细胞肺癌成人患者。奥...
2024-05-13 08:43
22亿美元，3月Biotech融资规模重回加息前
转自：新康界 3月，美国及欧洲的生物医药行业共发生16起融资事件，融资规模达21.97亿美元，其中值得关注的有： 自免药物领域：自免药物仍是行业热点，3月规模...
2024-04-22 16:18
BioMarin Announces Governance Enhancements and Value Creation Initiatives
Board Approves Appointment of Three New Independent Directors Company Establishes Strategic and Operating Review Committee of the Board BioMarin Enters into Cooperation and Information Shari...
2023-12-21 05:05
Acrivon Therapeutics Announces the Appointment of Adam Levy, Ph.D., M.B.A., Experienced Biotech Investor Relations and Strategy Executive, to Senior Vice President and Head, Investor Relations and Corporate Affairs
Dr. Levy brings more than 25 years of biopharma industry experience, including ...
2023-07-20 20:00
